Medications
have different
dosing and
administration
instructions

For adults with type 2
diabetes, along with
diet and exercise

JARDIANCE offers
convenient
once-daily oral
dosing

For adults with type 2
diabetes, along with
diet and exercise

10 mg

The recommended dose for JARDIANCE is 10 mg once daily

• The 10 mg starting dose of
  JARDIANCE provides glycemic
  control and CV death risk reduction
  in adult T2D patients who also have<
  established CVD1
• In patients who tolerate JARDIANCE
  10 mg, the dose can be increased to
  25 mg once daily

For adults with type 2
diabetes, along with
diet and exercise

JARDIANCE is taken with or
without food in the morning

• No fasting requirements before or
   after taking JARDIANCE

For adults with type 2
diabetes, along with
diet and exercise

No dose adjustment of
JARDIANCE is recommended
when coadministered with
commonly prescribed
medications

Important Dosing Considerations:

• Assess renal function before
   initiating JARDIANCE and as
   clinically indicated
• In patients with volume depletion,
   correct this condition before
   initiating JARDIANCE
• A lower dose of insulin or insulin
   secretagogues (eg, sulfonylureas)
   may be required to reduce the
   risk of hypoglycemia when
   JARDIANCE is used in combination
   with these agents
• JARDIANCE is contraindicated in
   patients with a hypersensitivity to
   empagliflozin or any of the
   excipients in JARDIANCE
   (reactions such as angioedema
   have occurred) and in patients on
   dialysis

Dosing in patients with renal impairment:

• JARDIANCE is not recommended
   for use in patients with an
   eGFR <30 mL/min/1.73 m2 and is
   contraindicated in patients on
   dialysis

See what
JARDIANCE can
do for your
patients

Not for type 1 diabetes, or type 2 diabetes
with an eGFR <30 mL/min/1.73 m2

LEARN MORE  >

Prescribing Information and Medication Guide

IMPORTANT SAFETY INFORMATION AND INDICATION

CONTRAINDICATIONS: Hypersensitivity to empagliflozin or any of the excipients in JARDIANCE, reactions such as angioedema have occurred; patients on dialysis.

WARNINGS AND PRECAUTIONS

Ketoacidosis: Ketoacidosis, a serious life-threatening condition requiring urgent hospitalization, has been identified in patients with type 1 and type 2 diabetes mellitus receiving SGLT2 inhibitors, including empagliflozin. Fatal cases of ketoacidosis have been reported in patients taking empagliflozin. Patients who present with signs and symptoms of metabolic acidosis should be assessed for ketoacidosis, even if blood glucose levels are less than 250 mg/dL. If suspected, discontinue JARDIANCE, evaluate, and treat promptly. Before initiating JARDIANCE, consider risk factors for ketoacidosis. Patients may require monitoring and temporary discontinuation in situations known to predispose to ketoacidosis. For patients who undergo scheduled surgery, consider temporarily discontinuing JARDIANCE for at least 3 days prior to surgery.

Volume Depletion: Empagliflozin can cause intravascular volume depletion which may manifest as symptomatic hypotension or acute transient changes in creatinine. Acute kidney injury requiring hospitalization and dialysis has been reported in patients with type 2 diabetes receiving SGLT2 inhibitors, including empagliflozin. Before initiating, assess volume status and renal function in patients with impaired renal function (eGFR <60 mL /min/1.73 m2), elderly patients or patients on loop diuretics. In patients with volume depletion, correct this condition. After initiating, monitor for signs and symptoms of volume depletion and renal function.

Urosepsis and Pyelonephritis: Serious urinary tract infections including urosepsis and pyelonephritis requiring hospitalization have been identified in patients receiving SGLT2 inhibitors, including empagliflozin. Treatment with SGLT2 inhibitors increases the risk for urinary tract infections. Evaluate for signs and symptoms of urinary tract infections and treat promptly.

Hypoglycemia: The use of JARDIANCE in combination with insulin or insulin secretagogues can increase the risk of hypoglycemia. A lower dose of insulin or the insulin secretagogue may be required.

Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene): Serious, life-threatening cases requiring urgent surgical intervention have occurred in both females and males. Serious outcomes have included hospitalization, multiple surgeries, and death. Assess patients presenting with pain or tenderness, erythema, or swelling in the genital or perineal area, along with fever or malaise. If suspected, institute prompt treatment and discontinue JARDIANCE.

Genital Mycotic Infections: Empagliflozin increases the risk for genital mycotic infections, especially in patients with prior infections. Monitor and treat as appropriate.

Hypersensitivity Reactions: Serious hypersensitivity reactions have occurred with JARDIANCE (angioedema). If hypersensitivity reactions occur, discontinue JARDIANCE, treat promptly, and monitor until signs and symptoms resolve.

MOST COMMON ADVERSE REACTIONS (≥5%): Urinary tract infections and female genital mycotic infections.

DRUG INTERACTIONS: Coadministration with diuretics may enhance the potential for volume depletion. Monitor for signs and symptoms.

USE IN SPECIAL POPULATIONS

Pregnancy: JARDIANCE is not recommended during the second and third trimesters.

Lactation: JARDIANCE is not recommended while breastfeeding.

Geriatric Use: JARDIANCE is expected to have diminished efficacy in elderly patients with renal impairment. Renal function should be assessed more frequently in elderly patients. The incidence of volume depletion-related adverse reactions and urinary tract infections increased in patients ≥75 years treated with empagliflozin.

CL‑JAR‑100092 08.18.2021

INDICATIONS AND LIMITATIONS OF USE

JARDIANCE is indicated:

  • to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure and reduced ejection fraction.
  • to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.
  • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

JARDIANCE is not recommended in patients with type 1 diabetes mellitus. It may increase their risk of diabetic ketoacidosis.

JARDIANCE is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR <30 mL/min/1.73 m2. JARDIANCE is likely to be ineffective in this setting based upon its mechanism of action.

Please see Prescribing Information and Medication Guide.

T2D=Type 2 Diabetes; CV=cardiovascular; CVD=cardiovascular disease; eGFR=estimated glomerular filtration rate.

References: 1. Zinman B, Wanner C, Lachin JM, et al; EMPA‑REG OUTCOME Investigators. N Engl J Med. 2015;373(22):2117‑2128. 2. Das SR, Everett BM, Birtcher KK, et al. J Am Coll Cardiol. 2018;72(24):3200‑3223.

Copyright © 2021 Boehringer
Ingelheim Pharmaceuticals, Inc.
All rights reserved.
(08/21) PC-US-122694B